Background[1-3]
The tartrate-resistant acid phosphatase (STRACP) kit (colorimetric method) can measure the tartrate-resistant acid phosphatase activity in various animal serum (plasma), tissue and other samples. The activity of tartrate-resistant acid phosphatase (StrACP) is not inhibited by tartaric acid, while other ACPs are inhibited by tartaric acid. The activity of StrACP can be determined by using this principle, imported from Germany. StrACP enzyme catalyzes the hydrolysis of the substrate to produce free phenol; phenol reacts with diazonium salts to produce colored azo compounds, which are measured colorimetrically at 530nm and the activity of the enzyme can be measured through calculation.
Structure of tartrate acid phosphatase (STRACP)
Tartrate-resistant acid phosphatase (StrACP) is an isoenzyme present in osteoclasts and is a very valuable indicator of bone resorption. Bone resorption increases and StrACP increases significantly. After surgical treatment of hyperparathyroidism cases, StrACP was significantly reduced. StrACP in primary osteoporosis was negatively correlated with ulnar, radial, and QCT vertebral bone density. StrACP was significantly reduced in parathyroid reduction cases.
Advantages:
1. Quick and easy: the whole process takes about 40 minutes and can test about 80 samples;
2. Micro sampling volume: 50ul for normal operation,
3. Good stability: the kit is effective for 6 months when stored at 2-8℃;
4. Good reproducibility: coefficient of variation CV=1.2%;
5. Recovery test: X=99%;
6. Small influence from external factors: few interference factors and strong repeatability;
7. Wide range of testing: can test animal serum (plasma), tissue, various body fluids, perfusion fluid, various cultured cells, and cell culture supernatants.
Apply[4][5]
For research on the expression and significance of serum tartrate-resistant acid phosphatase 5b in bone tumors
Expression of serum tartrate-resistant acid phosphatase 5b (TRACP5b) in patients with bone tumors and its clinical diagnostic value.
Methods: Enzyme-linked immunosorbent assay (ELISA) was used to detect patients with pathologically confirmed bone tumors (21 cases in the primary malignant bone tumor group, 31 cases in the primary benign bone tumor group, and 30 cases in the malignant tumor bone metastasis group). (example) and 37 healthy controls, serum TRACP5b expression levels, and serum alkaline phosphatase (ALP) expression values of the same patients were collected in the hospital laboratory department at the same time, and the results were analyzed. Results The serum TRACP5b concentration of patients in the bone tumor group (5.873±2.898) U/L was significantly higher than that of the healthy control group (3.651±1.124) U/L, and the difference was statistically significant (P<0.01).
The serum TRACP5b concentration of the primary malignant tumor (6.445±3.426) U/L and the malignant tumor bone metastasis group (6.683±2.764) U/L was higher than that of the normal control group (3.651±1.124) U/L, and the differences were statistically significant scientific significance (P<0.01). The U/L serum TRACP5b concentration in the malignant tumor bone metastasis group was significantly higher than that in the primary benign bone tumor group (4.724±2.264), and the difference was statistically significant (P<0.05).
The sensitivity of serum TRACP5b in diagnosing bone tumors is 76.8%, and the specificity is 62.2%. The sensitivity of ALP in diagnosing bone tumors is 69.5%, and the specificity is 54.1%. Serum TRACP5b concentration was positively correlated with ALP concentration, correlation coefficient r=0.427, P<0.01).
Conclusion TRACP5b is one of the serum markers of bone tumors. Serum TRACP5b is a sensitive and simple biochemical indicator that reflects the bone metabolism of bone tumors. It is of certain significance for the diagnosis and differential diagnosis of bone tumors.
